Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy
Different types of canine lymphoma respond differently to chemotherapy and have different prognoses. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in dogs. Topoisomerase II alpha (TOPIIα) protein has been shown to be a proliferation marker associated with prognostic significance....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Animals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2615/11/4/1183 |
| _version_ | 1797536982412296192 |
|---|---|
| author | Paweł Klimiuk Wojciech Łopuszyński Kamila Bulak Adam Brzana |
| author_facet | Paweł Klimiuk Wojciech Łopuszyński Kamila Bulak Adam Brzana |
| author_sort | Paweł Klimiuk |
| collection | DOAJ |
| description | Different types of canine lymphoma respond differently to chemotherapy and have different prognoses. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in dogs. Topoisomerase II alpha (TOPIIα) protein has been shown to be a proliferation marker associated with prognostic significance. The aim of the study was to determine the relationship between TOPIIα expression, mitotic count (MC), and Ki67 antigen index in DLBCL in dogs, taking into account the applicability of these parameters to select the chemotherapy protocol with emphasis on the use of anthracycline drugs. Samples of formalin-fixed paraffin-embedded lymph nodes from 34 dogs with DLBCL were immunohistochemically labelled with anti-TOPIIα and Ki67. The number of positive cells and the intensity of the reaction were taken into account in order to assess TOPIIα expression. MC was estimated in the hematoxylin and eosin-stained slides in the area of 2.37 mm<sup>2</sup>. Positive association between TOPIIα and MC, but no association between TOPIIα and Ki67 was found. It can be concluded that the immunohistochemical determination of TOPIIα as a molecular target for drugs from the anthracycline group may be used in association with MC to establish a diagnostic-clinical protocol for selecting dogs with DLBCL for treatment with anthracycline drugs. |
| first_indexed | 2024-03-10T12:08:35Z |
| format | Article |
| id | doaj.art-659abe3f35434ccd8e616844e7804f82 |
| institution | Directory Open Access Journal |
| issn | 2076-2615 |
| language | English |
| last_indexed | 2024-03-10T12:08:35Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Animals |
| spelling | doaj.art-659abe3f35434ccd8e616844e7804f822023-11-21T16:23:43ZengMDPI AGAnimals2076-26152021-04-01114118310.3390/ani11041183Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based ChemotherapyPaweł Klimiuk0Wojciech Łopuszyński1Kamila Bulak2Adam Brzana3Veterinary Diagnostic Laboratory VetDiagnostyka, 20-418 Lublin, PolandSub-Department of Pathomorphology and Forensic Veterinary Medicine, Department and Clinic of Animal Internal Diseases, University of Life Sciences in Lublin, 20-601 Lublin, PolandSub-Department of Pathomorphology and Forensic Veterinary Medicine, Department and Clinic of Animal Internal Diseases, University of Life Sciences in Lublin, 20-601 Lublin, PolandRegional Veterinary Inspectorate in Opole, Regional Veterinary Laboratory, 45-836 Opole, PolandDifferent types of canine lymphoma respond differently to chemotherapy and have different prognoses. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in dogs. Topoisomerase II alpha (TOPIIα) protein has been shown to be a proliferation marker associated with prognostic significance. The aim of the study was to determine the relationship between TOPIIα expression, mitotic count (MC), and Ki67 antigen index in DLBCL in dogs, taking into account the applicability of these parameters to select the chemotherapy protocol with emphasis on the use of anthracycline drugs. Samples of formalin-fixed paraffin-embedded lymph nodes from 34 dogs with DLBCL were immunohistochemically labelled with anti-TOPIIα and Ki67. The number of positive cells and the intensity of the reaction were taken into account in order to assess TOPIIα expression. MC was estimated in the hematoxylin and eosin-stained slides in the area of 2.37 mm<sup>2</sup>. Positive association between TOPIIα and MC, but no association between TOPIIα and Ki67 was found. It can be concluded that the immunohistochemical determination of TOPIIα as a molecular target for drugs from the anthracycline group may be used in association with MC to establish a diagnostic-clinical protocol for selecting dogs with DLBCL for treatment with anthracycline drugs.https://www.mdpi.com/2076-2615/11/4/1183malignant lymphomadogcell proliferationchemotherapyKi67topoisomerase IIα |
| spellingShingle | Paweł Klimiuk Wojciech Łopuszyński Kamila Bulak Adam Brzana Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy Animals malignant lymphoma dog cell proliferation chemotherapy Ki67 topoisomerase IIα |
| title | Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy |
| title_full | Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy |
| title_fullStr | Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy |
| title_full_unstemmed | Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy |
| title_short | Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy |
| title_sort | evaluation of the proliferative activity of diffuse large b cell lymphoma dlbcl in dogs with respect to patient eligibility for anthracycline based chemotherapy |
| topic | malignant lymphoma dog cell proliferation chemotherapy Ki67 topoisomerase IIα |
| url | https://www.mdpi.com/2076-2615/11/4/1183 |
| work_keys_str_mv | AT pawełklimiuk evaluationoftheproliferativeactivityofdiffuselargebcelllymphomadlbclindogswithrespecttopatienteligibilityforanthracyclinebasedchemotherapy AT wojciechłopuszynski evaluationoftheproliferativeactivityofdiffuselargebcelllymphomadlbclindogswithrespecttopatienteligibilityforanthracyclinebasedchemotherapy AT kamilabulak evaluationoftheproliferativeactivityofdiffuselargebcelllymphomadlbclindogswithrespecttopatienteligibilityforanthracyclinebasedchemotherapy AT adambrzana evaluationoftheproliferativeactivityofdiffuselargebcelllymphomadlbclindogswithrespecttopatienteligibilityforanthracyclinebasedchemotherapy |